tirzepatide into muscle Tirzepatide‐induced body composition changes: Implications from the SURPASS‐3 MRI substudy Protein Pacing on Tirzepatide: Protect

They might overshoot the dose on the label, anticipating the loss in stability while in storage

At 36 weeks, the drug is withdrawn from some participants whose bodies then return to their normal function and try desperately to return to stasis (which is a process that we see in non-drug induced weight loss from behavioral interventions when, after about a year of weight loss people begin to regain weight, with the vast majority regaining all of the weight they lost.) Remember, too, that they know they are part of a trial and that they may continue getting the trial drug, or they may be getting a placebo

The pharmaceutical version remains in Phase 3 clinical trials, with FDA approval expected between late 2026 and early 2027

While Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist, Zepbound offers a dual GLP-1/GIP approach, and Mounjaro combines effects on both GIP and GLP-1 receptors for enhanced metabolic benefits